{"id":355256,"date":"2026-11-19T14:29:01","date_gmt":"2026-11-19T08:59:01","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355256"},"modified":"2026-11-19T14:29:01","modified_gmt":"2026-11-19T08:59:01","slug":"laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/","title":{"rendered":"Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Laurus_Labs_Share_Price_845_CAGR_in_3_Years_as_the_Hyderabad-Based_API_Maker_Compares_With_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals\" title=\"Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals\">Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_Much_Has_the_Laurus_Labs_Share_Price_Returned_in_3_Years\" title=\"How Much Has the Laurus Labs Share Price Returned in 3 Years?\">How Much Has the Laurus Labs Share Price Returned in 3 Years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Laurus_Labs_vs_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals_3-Year_CAGR_Compared\" title=\"Laurus Labs vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared\">Laurus Labs vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Valuation_and_Quality_Compared\" title=\"Valuation and Quality Compared\">Valuation and Quality Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_Is_Driving_the_Laurus_Labs_Stock\" title=\"What Is Driving the Laurus Labs Stock?\">What Is Driving the Laurus Labs Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_the_Established_Players_Stack_Up\" title=\"How the Established Players Stack Up\">How the Established Players Stack Up<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_Should_Investors_Track_Next\" title=\"What Should Investors Track Next?\">What Should Investors Track Next?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_to_Compare_Pharma_Stocks_Yourself\" title=\"How to Compare Pharma Stocks Yourself\">How to Compare Pharma Stocks Yourself<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#An_API_and_CDMO_Maker_Beside_Three_Pharma_Names\" title=\"An API and CDMO Maker Beside Three Pharma Names\">An API and CDMO Maker Beside Three Pharma Names<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_is_the_Laurus_Labs_share_price_today\" title=\"What is the Laurus Labs share price today?\">What is the Laurus Labs share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_is_the_3-year_CAGR_of_the_Laurus_Labs_stock\" title=\"What is the 3-year CAGR of the Laurus Labs stock?\">What is the 3-year CAGR of the Laurus Labs stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Is_Laurus_Labs_better_than_Lupin\" title=\"Is Laurus Labs better than Lupin?\">Is Laurus Labs better than Lupin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_does_Laurus_Labs_do\" title=\"What does Laurus Labs do?\">What does Laurus Labs do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Is_the_Laurus_Labs_stock_debt_free\" title=\"Is the Laurus Labs stock debt free?\">Is the Laurus Labs stock debt free?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Is_Laurus_Labs_expensive_compared_with_the_industry\" title=\"Is Laurus Labs expensive compared with the industry?\">Is Laurus Labs expensive compared with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Which_pharma_stock_gave_the_highest_return_in_3_years\" title=\"Which pharma stock gave the highest return in 3 years?\">Which pharma stock gave the highest return in 3 years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_do_I_calculate_CAGR_for_a_stock\" title=\"How do I calculate CAGR for a stock?\">How do I calculate CAGR for a stock?<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"Laurus_Labs_Share_Price_845_CAGR_in_3_Years_as_the_Hyderabad-Based_API_Maker_Compares_With_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals\"><\/span><strong>Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Laurus Labs previous close Rs 2,322.50. 3-year CAGR 84.5%. Up 6.3x since 17 Nov 2023. ROE 22.11%. Market cap Rs 1,25,461 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Laurus Labs share price<\/strong> closed at Rs 2,322.50 on 18 November 2026, a compounded annual return of <strong>84.5%<\/strong> over three years. That compares with Zydus Lifesciences at 23.6%, Lupin at 18.1% and Glenmark Pharmaceuticals at 50.5%. The company has a <strong>market cap<\/strong> of Rs 1,25,461 crore and a P\/E of 94.16 against an industry P\/E of 40.12.<\/p>\n<\/p><\/div>\n<p>The <strong>Laurus Labs share price<\/strong> closed at Rs 2,322.50 on 18 November 2026 and has compounded at <strong>84.5%<\/strong> a year over three years, which means the stock has gained about 6.3 times and leads the four pharma companies compared here. Laurus Labs, based in Hyderabad, makes <strong>active pharmaceutical ingredients<\/strong>, finished formulations and <strong>contract development<\/strong> services.<\/p>\n<p>This article places that run beside Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals. We calculate the <strong>three-year CAGR<\/strong> for all four and set the results next to market cap, valuation, <strong>return on equity<\/strong> and debt, using prices adjusted for corporate actions.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=laurus-labs-share-price\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_the_Laurus_Labs_Share_Price_Returned_in_3_Years\"><\/span><strong>How Much Has the Laurus Labs Share Price Returned in 3 Years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Laurus Labs stock<\/strong> closed at Rs 369.85 on 17 November 2023 and at Rs 2,322.50 on 18 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 6.28 lakh, which is a <strong>CAGR<\/strong> of <strong>84.5%<\/strong>. This is a price return and leaves out dividends.<\/p>\n<p>CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Laurus Labs can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.<\/p>\n<p>A company that supplies ingredients and development services earns on volumes and long term supply contracts, so the price follows capacity and customer wins. The <strong>Laurus Labs share price<\/strong> shows how fast such a business can rerate when new segments scale.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Laurus_Labs_vs_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals_3-Year_CAGR_Compared\"><\/span><strong>Laurus Labs vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table ranks the companies by three-year CAGR. Prices on 17 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 18 November 2026.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Close on 17 Nov 2023<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Previous close (18 Nov 2026)<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Price multiple<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">3-year CAGR<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Laurus Labs<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 369.85<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 2,322.50<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">6.3x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">84.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Glenmark Pharmaceuticals<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 775.95<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 2,646.10<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">3.4x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">50.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 636.55<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,202.00<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.9x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">23.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Lupin<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,196.30<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,971.90<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.6x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">18.1%<\/td>\n<\/tr>\n<\/table>\n<p>The <strong>Laurus Labs stock<\/strong> leads the group at <strong>84.5%<\/strong>, followed by Glenmark Pharmaceuticals at 50.5%, Zydus Lifesciences at 23.6% and Lupin at 18.1%. By market cap the company ranks first of the four at Rs 1,25,461 crore. Laurus Labs is the largest of the four by market cap.<\/p>\n<p>Look at the <strong>Laurus Labs share price<\/strong> alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_and_Quality_Compared\"><\/span><strong>Valuation and Quality Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Market cap<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Debt to equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/lauruslabs\/laurus-labs-ltd-share-price-today\">Laurus Labs<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,25,461 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">94.16<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">22.11%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.43<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,19,202 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">27.71<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">15.10%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.50<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 90,039 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">17.24<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">21.65%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.26<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 74,931 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">51.63<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">18.07%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.13<\/td>\n<\/tr>\n<\/table>\n<p>By market cap, Laurus Labs is the largest of the group at Rs 1,25,461 crore, which gives it the scale advantage over Zydus Lifesciences, Lupin, Glenmark Pharmaceuticals. On earnings, Laurus Labs shares trade at a P\/E of 94.16 against an industry P\/E of 40.12, a premium of about 135%, which signals that the market expects faster earnings growth. Peer multiples are Zydus Lifesciences at 27.71, Lupin at 17.24 and Glenmark Pharmaceuticals at 51.63.<\/p>\n<p>Return on equity is 22.11% for the Laurus Labs stock, which ranks first among the four, and <strong>debt to equity<\/strong> stands at 0.43. Trailing EPS is Rs 24.66. Laurus Labs trades at a P\/E of 94.16 against an industry P\/E of 40.12, with a price to book of 20.70. Its ROE of 22.11% is the highest in the group.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_the_Laurus_Labs_Stock\"><\/span><strong>What Is Driving the Laurus Labs Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Laurus earns revenue from active ingredients for antiretroviral and other medicines, finished formulations, and a contract development business that works with global drug makers. New segments add to its base over time.<\/p>\n<p>The company earns an ROE of 22.11%, which is the highest in the group, and carries a debt to equity of 0.43. Its P\/E of 94.16 sits well above the industry P\/E of 40.12.<\/p>\n<p>Investors who follow the <strong>Laurus Labs share price<\/strong> usually track capacity additions, contract development wins, margin on ingredients and progress in newer segments.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_the_Established_Players_Stack_Up\"><\/span><strong>How the Established Players Stack Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences is an Ahmedabad-based drug maker with generics, branded medicines and a vaccines business. It compounded at 23.6% a year, on a market cap of Rs 1,19,202 crore and an ROE of 15.10%.<\/p>\n<p>Lupin is a Mumbai-based drug maker with a strong presence in respiratory and cardiovascular medicines. It compounded at 18.1% a year, on a market cap of Rs 90,039 crore and an ROE of 21.65%.<\/p>\n<p>Glenmark Pharmaceuticals is a Mumbai-based drug maker with a presence in dermatology and respiratory therapies. It compounded at 50.5% a year, on a market cap of Rs 74,931 crore and an ROE of 18.07%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Track_Next\"><\/span><strong>What Should Investors Track Next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three things are worth watching on the <strong>Laurus Labs share price<\/strong>. First, growth in its contract development business. Second, margin on ingredients and formulations. Third, capacity additions and utilisation.<\/p>\n<p>At a P\/E of 94.16 the stock trades well above the industry P\/E of 40.12, so expectations are already high. Order timing can move results, so follow each result closely.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals of pharma stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Pharma_Stocks_Yourself\"><\/span><strong>How to Compare Pharma Stocks Yourself<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>You can repeat this exercise for any pair of stocks, including the Laurus Labs stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P\/E against the industry P\/E, ROE and debt to equity. Benchmark the result against the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> as well, so you know whether the stock beat the broader market.<\/p>\n<p>A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the <strong>Laurus Labs share price<\/strong>, the same four checks give a more complete picture than price alone.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the <strong>Laurus Labs share price<\/strong> and compare pharma stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"An_API_and_CDMO_Maker_Beside_Three_Pharma_Names\"><\/span><strong>An API and CDMO Maker Beside Three Pharma Names<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Laurus Labs share price<\/strong> compounded at 84.5% a year over three years, against 50.5% for Glenmark, 23.6% for Zydus and 18.1% for Lupin. Its ROE of 22.11% is the highest of the four.<\/p>\n<p>Laurus Labs brings the fastest return, Laurus Labs brings the highest ROE and Lupin brings the lowest P\/E. Laurus Labs offers an ingredient and development focus, which the other three mix with branded medicines.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Laurus_Labs_share_price_today\"><\/span><strong>What is the Laurus Labs share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Laurus Labs closed at Rs 2,322.50 on 18 November 2026, according to NSE data. It has a market cap of Rs 1,25,461 crore and a P\/E of 94.16. Check live quotes before acting, as prices change every trading day.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_3-year_CAGR_of_the_Laurus_Labs_stock\"><\/span><strong>What is the 3-year CAGR of the Laurus Labs stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Laurus Labs delivered a price CAGR of 84.5% over three years, moving from Rs 369.85 on 17 November 2023 to Rs 2,322.50 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Laurus_Labs_better_than_Lupin\"><\/span><strong>Is Laurus Labs better than Lupin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Laurus Labs delivered the higher three-year CAGR at 84.5% against 18.1% for Lupin. Laurus Labs has the larger market cap at Rs 1,25,461 crore against Rs 90,039 crore for Lupin. Laurus Labs earns the higher ROE at 22.11% against 21.65%. Lupin trades at the lower P\/E of 17.24 against 94.16. The better choice depends on whether you weigh recent return, size, profitability or valuation most.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Laurus_Labs_do\"><\/span><strong>What does Laurus Labs do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Laurus Labs Limited is a Hyderabad-based pharmaceutical company that makes active pharmaceutical ingredients and finished formulations and offers contract development and manufacturing services.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Laurus_Labs_stock_debt_free\"><\/span><strong>Is the Laurus Labs stock debt free?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio of the Laurus Labs stock is 0.43 and its return on equity is 22.11%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Laurus_Labs_expensive_compared_with_the_industry\"><\/span><strong>Is Laurus Labs expensive compared with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Laurus Labs trades at a P\/E of 94.16 against an industry P\/E of 40.12. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_gave_the_highest_return_in_3_years\"><\/span><strong>Which pharma stock gave the highest return in 3 years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the companies compared here, Laurus Labs delivered the highest three-year CAGR at 84.5%, followed by Glenmark Pharmaceuticals at 50.5%. Past returns do not guarantee future performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_calculate_CAGR_for_a_stock\"><\/span><strong>How do I calculate CAGR for a stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Laurus Labs share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Laurus Labs closed at Rs 2,322.50 on 18 November 2026, according to NSE data. It has a market cap of Rs 1,25,461 crore and a P\/E of 94.16. Check live quotes before acting, as prices change every trading day.\"}},{\"@type\":\"Question\",\"name\":\"What is the 3-year CAGR of the Laurus Labs stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Laurus Labs delivered a price CAGR of 84.5% over three years, moving from Rs 369.85 on 17 November 2023 to Rs 2,322.50 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Is Laurus Labs better than Lupin?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Laurus Labs delivered the higher three-year CAGR at 84.5% against 18.1% for Lupin. Laurus Labs has the larger market cap at Rs 1,25,461 crore against Rs 90,039 crore for Lupin. Laurus Labs earns the higher ROE at 22.11% against 21.65%. Lupin trades at the lower P\/E of 17.24 against 94.16. The better choice depends on whether you weigh recent return, size, profitability or valuation most.\"}},{\"@type\":\"Question\",\"name\":\"What does Laurus Labs do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Laurus Labs Limited is a Hyderabad-based pharmaceutical company that makes active pharmaceutical ingredients and finished formulations and offers contract development and manufacturing services.\"}},{\"@type\":\"Question\",\"name\":\"Is the Laurus Labs stock debt free?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio of the Laurus Labs stock is 0.43 and its return on equity is 22.11%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.\"}},{\"@type\":\"Question\",\"name\":\"Is Laurus Labs expensive compared with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Laurus Labs trades at a P\/E of 94.16 against an industry P\/E of 40.12. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock gave the highest return in 3 years?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the companies compared here, Laurus Labs delivered the highest three-year CAGR at 84.5%, followed by Glenmark Pharmaceuticals at 50.5%. Past returns do not guarantee future performance.\"}},{\"@type\":\"Question\",\"name\":\"How do I calculate CAGR for a stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Laurus Labs share price compounded at 84.5% a year over 3 years. See how it compares with peers on returns and valuation.<\/p>\n","protected":false},"author":38,"featured_media":355255,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[16446,26224,26223,19413],"class_list":["post-355256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-laurus-labs-share-price","tag-laurus-labs-stock","tag-laurus-labs-vs-lupin","tag-pharma-stocks-3-year-return"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355255"],"rank_math_title":["Laurus Labs Share Price: 84.5% CAGR vs Zydus, Lupin"],"rank_math_description":["Laurus Labs share price compounded at 84.5% a year over 3 years. See how it compares with peers on returns and valuation."],"rank_math_focus_keyword":["Laurus Labs share price | Density Target: 1.2-1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/laurus-labs-share-price-84-5-cagr-in-3-years-as-the-hyderabad-based-api-maker.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355256"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355256\/revisions"}],"predecessor-version":[{"id":355257,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355256\/revisions\/355257"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355255"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}